Lestaurtinib Inhibition of the JAKSTAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis

Diaz, Tania ; Navarro, Alfons ; Ferrer, Gerardo ; Gel, Bernat ; Gaya, Anna ; Artells, Rosa ; Bellosillo, Beatriz ; Garcia-Garcia, Mar ; Serrano, Sergi ; Martínez, Antonio ; Monzo, Mariano ; Nogales-Gadea, Gisela

Resumen: Standard cytotoxic chemotherapy for Hodgkin Lymphoma (HL) has changed little in 30 years; the treatment for patients with relapsed or refractory disease remains challenging and novel agents are under development. JAK/STAT constitutive activation plays an important role in the pathogenesis of HL. Lestaurtinib is an orally bioavailable multikinase inhibitor that has recently been shown to inhibit JAK2 in myeloproliferative disorders. The potential role of Lestaurtinib in HL therapy is unknown. We have analyzed the effect of Lestaurtinib treatment in five HL cell lines from refractory patients, L-428, L-1236, L-540, HDML-2 and HD-MY-Z. At 48 h, a dose-dependent cell growth inhibition (23%–66% at 300 nM) and apoptotic increment (10%–64% at 300 nM) were observed. Moreover, Lestaurtinib inhibited JAK2, STAT5 and STAT3 phosphorylation and reduced the mRNA expression of its downstream antiapoptotic target Bcl-xL. In addition, we have analyzed the effect of Lestaurtinib treatment in lymph nodes from four classic HL patients. We observed a decrease in cell viability at 24 hours of treatment in three patients (mean decrease of 27% at 300 nM). Our findings provide, for the first time, a molecular rationale for testing JAK2 inhibitors, specifically Lestaurtinib, in HL patients.

Idioma: Inglés

DOI: 10.1371/journal.pone.0018856

Año: 2011

Publicado en: PLoS ONE 6, 4 (2011), e18856 [7 pp.]
ISSN: 1932-6203

Factor impacto JCR: 4.092 (2011)

Categ. JCR: BIOLOGY rank: 12 / 85 = 0.141 (2011) - Q1 - T1

Tipo y forma: Artículo (Versión definitiva)